Seeking Alpha

Genentech, a Roche (RHHBY.PK) subsidiary, says the FDA has expanded the approved indication for...

Genentech, a Roche (RHHBY.PK) subsidiary, says the FDA has expanded the approved indication for Actemra for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs. The drug can be used both alone as a single-agent therapy and in combination with other treatments.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|